

HR 7400

American Made Pharmaceuticals Act of 2022

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Apr 5, 2022

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Apr 6, 2022)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/7400>

Sponsor

Name: Rep. Craig, Angie [D-MN-2]

Party: Democratic • State: MN • Chamber: House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Mullin, Markwayne [R-OK-2]	R · OK		Apr 5, 2022

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Apr 6, 2022
Ways and Means Committee	House	Referred To	Apr 5, 2022

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 S 3991	Identical bill	Apr 5, 2022: Read twice and referred to the Committee on Finance.

American Made Pharmaceuticals Act of 2022

This bill requires the Centers for Medicare & Medicaid Services to conduct a demonstration program that gives preference to domestically manufactured drugs under Medicare, Medicaid, and the Children's Health Insurance Program (CHIP).

The program must be conducted in at least eight states and for at least seven years. Applicable drugs include critical drugs that are needed to respond to a public health emergency and that have a vulnerable global supply chain. Preference may take the form of reduced cost-sharing, preferential treatment on formularies, bonus payments, and other specified methods.

Actions Timeline

- **Apr 6, 2022:** Referred to the Subcommittee on Health.
- **Apr 5, 2022:** Introduced in House
- **Apr 5, 2022:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.